Compare CCM & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | FEMY |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 22.4M |
| IPO Year | 2009 | 2021 |
| Metric | CCM | FEMY |
|---|---|---|
| Price | $2.94 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 11.3K | ★ 67.0K |
| Earning Date | 10-06-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $3.18 | $0.29 |
| 52 Week High | $6.96 | $6.29 |
| Indicator | CCM | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.40 |
| Support Level | N/A | $0.41 |
| Resistance Level | N/A | $3.21 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 27.12 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.